SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today announced that data presented over the weekend at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium (ENA 2020), showed that zotatifin, the company’s product candidate targeting eIF4A, downregulates key cancer-driving proteins including receptor tyrosine kinase (RTK)

Leading institutional investors commit $500 million through concurrent equity investments Upon completion of the business combination, over $850 million of expected cash resources will be used to advance development of Nuvation Bio’s wholly-owned deep pipeline of differentiated and novel investigational oncology therapeutic candidates Nuvation Bio shareholders, Panacea shareholders and equity financing investors will hold shares in the Combined Company to be led by CEO David

Boston Consulting Group, Shopify, Barclays, JPMorgan Chase, Givewith, IBM, Dogfish Head Craft Brewery, and New Belgium Brewing commit to supporting growers through agricultural carbon credits. Credits will be issued using new greenhouse gas (GHG) offset project methodologies developed by the Climate Action Reserve and Verra. With farms representing millions of acres already participating in the Indigo Carbon program, US farmers are poised to begin earning additional income fr

A pair of revolutionary leadless pacemakers have been successfully implanted into the heart of a patient in Melbourne in a world-first procedure. The exciting milestone — which was the work of cardiologists at Monash Health — used two already-available wireless devices to rejig the heart’s rhythm, without the need for wires to be connected into the heart. It’s the first time the pacemakers have been used in tandem to create the response, and as a first, not final, option. Mon

Several companies are exploring microbiome treatments for various ailments, ranging from Parkinson’s disease and multiple sclerosis to more usual suspects like gastrointestinal infections. One company, Federation Bio, thinks its approach can top the rest, and its new CEO—not to mention investors—agree. The company launches with $50 million and science so compelling it convinced Emily Drabant Conley, formerly 23andMe’s vice president of business development, to leave the genom